OTC Allergy Switch Approved For Bayer In US
Azelastine 0.15% Nasal Antihistamine Branded Astepro Allergy Is First-In-Class Switch
Executive Summary
CDER approves Bayer Healthcare’s azelastine 0.15% nasal antihistamine indicated for seasonal and perennial allergic rhinitis in adults and children 6 and older. Bayer says Astepro Allergy is first steroid-free antihistamine for allergies available OTC in the US and the first indicated for indoor and outdoor allergy relief.
You may also be interested in...
Sildenafil, Tadalafil Among Big Hitters On Upcoming German Switch Committee Agenda
Possible OTC switches of erectile dysfunction drugs sildenafil and tadalafil, as well as azelastine and fluticasone propionate combination nasal sprays and migraine drug rizatriptan, are on a packed agenda for the next meeting of the German Expert Committee on Prescription.
Bayer Blames Macroeconomic Pressures For Lower Volumes In Q1
Inflationary pressures and supply constraints led to volume declines at Bayer Consumer Health in Q1. However, price rises offset these headwinds helping the business to post a 4% rise in sales.
Alternative Smoking Cessation Drug Cytisine On 2023 German Switch Committee Agenda
Low-cost alternative smoking cessation drug cytisine is under consideration by Germany's independent switch committee in January, alongside azelastine and fluticasone propionate in combination for intranasal use, olopatadine for ophthalmic use and bilastine (10mg) for oral use.